Eagle Pharmaceuticals,Inc. (TLV:TEVA) Files An 8-K Other Events
Item 8.01 Other Events.
On December13, 2016, Eagle Pharmaceuticals,Inc. issued a press
release announcing positive results from its pivotal animal study
conducted under the U.S. Food and Drug Administrations so-called
Animal Rule, for RYANODEX for the treatment of exertional heat
stroke, an investigational new indication for the product.
A copy of the press release referenced above is filed as
Exhibit99.1 to this Current Report on Form8-K and is incorporated
herein by reference.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release dated December13, 2016 |
About Eagle Pharmaceuticals, Inc. (TLV:TEVA)
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women’s health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely. Eagle Pharmaceuticals, Inc. (TLV:TEVA) Recent Trading Information
Eagle Pharmaceuticals, Inc. (TLV:TEVA) closed its last trading session down -230.00 at 14,060.00 with 750,911 shares trading hands.
